Brought to you by 
Rosetta Genomics nets $26.2mm through IPO on Nasdaq
16 Oct 2007
Executive Summary
Rosetta Genomics, which uses micro-ribonucleic acid (miRNA) to treat and diagnose diseases, netted $26.2mm (including the overallotment) in its initial public offering on Nasdaq of 4.3mm ordinary shares at $7 each, slightly below its planned price range of $7.50-8.50. In September 2006, the company announced its intention to sell 3mm shares at $11-13 apiece.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Rosetta Genomics nets $26.2mm through IPO on Nasdaq
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice